These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15242881)

  • 21. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations.
    Zheng R; Friedman AD; Small D
    Blood; 2002 Dec; 100(12):4154-61. PubMed ID: 12393674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.
    Hunter HM; Pallis M; Seedhouse CH; Grundy M; Gray C; Russell NH
    Br J Haematol; 2004 Oct; 127(1):26-33. PubMed ID: 15384974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
    Brown P; Meshinchi S; Levis M; Alonzo TA; Gerbing R; Lange B; Arceci R; Small D
    Blood; 2004 Sep; 104(6):1841-9. PubMed ID: 15166029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
    Bagrintseva K; Geisenhof S; Kern R; Eichenlaub S; Reindl C; Ellwart JW; Hiddemann W; Spiekermann K
    Blood; 2005 May; 105(9):3679-85. PubMed ID: 15626738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
    Zwaan CM; Meshinchi S; Radich JP; Veerman AJ; Huismans DR; Munske L; Podleschny M; Hählen K; Pieters R; Zimmermann M; Reinhardt D; Harbott J; Creutzig U; Kaspers GJ; Griesinger F
    Blood; 2003 Oct; 102(7):2387-94. PubMed ID: 12816873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.
    Steudel C; Wermke M; Schaich M; Schäkel U; Illmer T; Ehninger G; Thiede C
    Genes Chromosomes Cancer; 2003 Jul; 37(3):237-51. PubMed ID: 12759922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
    Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
    Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
    Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.
    Uras IZ; Walter GJ; Scheicher R; Bellutti F; Prchal-Murphy M; Tigan AS; Valent P; Heidel FH; Kubicek S; Scholl C; Fröhling S; Sexl V
    Blood; 2016 Jun; 127(23):2890-902. PubMed ID: 27099147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
    Corbin AS; Griswold IJ; La Rosée P; Yee KW; Heinrich MC; Reimer CL; Druker BJ; Deininger MW
    Blood; 2004 Dec; 104(12):3754-7. PubMed ID: 15304388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of FLT3 in leukemia.
    Gilliland DG; Griffin JD
    Curr Opin Hematol; 2002 Jul; 9(4):274-81. PubMed ID: 12042700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
    Sattler M; Scheijen B; Weisberg E; Griffin JD
    Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.
    Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
    Christiansen DH; Pedersen-Bjergaard J
    Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
    Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FLT3 in human hematologic malignancies.
    Kiyoi H; Naoe T
    Leuk Lymphoma; 2002 Aug; 43(8):1541-7. PubMed ID: 12400596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flt3 receptor tyrosine kinase as a drug target in leukemia.
    Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
    Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific.
    Stirewalt DL; Willman CL; Radich JP
    Leuk Res; 2001 Dec; 25(12):1085-8. PubMed ID: 11684280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
    Whitman SP; Archer KJ; Feng L; Baldus C; Becknell B; Carlson BD; Carroll AJ; Mrózek K; Vardiman JW; George SL; Kolitz JE; Larson RA; Bloomfield CD; Caligiuri MA
    Cancer Res; 2001 Oct; 61(19):7233-9. PubMed ID: 11585760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.